Detalles de la búsqueda
1.
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Am J Hematol
; 98(6): 848-856, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36880203
2.
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
Cancer
; 128(3): 529-535, 2022 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34633671
3.
Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia.
Eur J Haematol
; 106(6): 851-858, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33721333
4.
Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 26(9): 1697-1703, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32534103
5.
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 26(8): 1425-1432, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32416253
6.
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant
; 26(6): 1084-1090, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035275
7.
Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.
Biol Blood Marrow Transplant
; 26(2): 292-299, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31536825
8.
Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia.
Transpl Infect Dis
; 22(2): e13233, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31840347
9.
Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.
Biol Blood Marrow Transplant
; 25(2): 287-292, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30227232
10.
Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant
; 25(2): 265-269, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30201397
11.
Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 24(9): 1828-1835, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29753158
12.
Refractory primary autoimmune myelofibrosis treated with ruxolitinib.
Am J Hematol
; 96(8): E283-E285, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33909922
13.
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy.
Leuk Lymphoma
; 64(6): 1092-1101, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37021793
14.
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
Transplant Cell Ther
; 29(8): 515.e1-515.e7, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37182736
15.
Large-scale manufacturing and characterization of CMV-CD19CAR T cells.
J Immunother Cancer
; 10(1)2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35027426
16.
Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation.
Leuk Lymphoma
; 63(5): 1220-1226, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34879769
17.
Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study.
Blood Adv
; 6(5): 1444-1453, 2022 03 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34581764
18.
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide.
Blood Adv
; 6(14): 4098-4106, 2022 07 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35838754
19.
Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL.
Blood Adv
; 6(17): 4936-4948, 2022 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35816633
20.
Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant.
Blood Adv
; 5(12): 2650-2659, 2021 06 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34156440